How effective are TNF inhibitors in axial spondyloarthritis?
Study of more than 24,000 registry patients shows real-world efficacy and adherence
About one in three patients with axial spondyloarthritis are likely to achieve inactive disease six months into therapy with a TNF inhibitor, a large registry study suggests.
The real-world analysis of patients naïve to biologics showed that 33% achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS) of below 1.3 at six months.
At baseline, median ASDAS score was 3.6.
After one and two years on therapy, 35% and 38% of patients, respectively, achieved ASDAS inactive disease.
